Radiolabeled anti-CD4 monoclonal antibody fragment (Biotectid)

N/A

Report date: 2025/09/15 17:34:07

Base Information

Drug NameRadiolabeled anti-CD4 monoclonal antibody fragment (Biotectid)

Drug Alias NameEP-1645[(99m)Tc]-EP164599mTc-EP1645

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Nuclides > Technetium > 99mTc +[5]

Mechanisms of ActionAnti-CD4

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsCarotid StenosisArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiotectid Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsCarotid StenosisArthritis, Rheumatoid

Other Information

ATC CodeN/A